Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 9, 2018 (9 years ago)

Cyclosporine USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Cyclosporine USP, for prescription compounding, packaged in a) 5g (NDC 58597-8210-2); b) 10g (NDC 58597-8210-3); c) 100g, NDC 58597-8210-6; d) 500g (NDC 58597-8210-7), RX only, packed by American Pharmaceutical Ingredients, LLC 6650 Highland Road, Waterford, MI 48327

Affected NDCs 58597-8210-02 58597-8210-03 58597-8210-06 58597-8210-07

Compare with the code on your package — it is the most precise check available.

Drug: Cyclosporine

Recalling firm
American Pharmaceutical Ingredients LLC
NDC code
58597-8210-2
Origin
MI, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0482-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Cyclosporine recalls

See all
Class I · High risk

SANDIMMUNE Oral Solution

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals

Ongoing Failed specification Novartis Pharmaceuticals Corporation NDC 0078-0110-22 D-0144-2024
Class I · High risk

SANDIMMUNE Oral Solution

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals.

Ongoing Failed specification Novartis Pharmaceuticals Corp. NDC 0078-0110-22 D-1174-2023

Other recalls by American Pharmaceutical Ingredients LLC

All 2018 recalls
Class II · Moderate risk

Sermorelin Acetate

Stability Data Does Not Support Expiry: Stability data from manufacturer does not support expiration dates listed.

Terminated Stability / shelf life American Pharmaceutical Ingredients LLC NDC 58597-8092-1 D-0592-2018
Class II · Moderate risk

Oxytocin USP

Stability Data Does Not Support Expiry: Stability data from manufacturer does not support expiration dates listed.

Terminated Stability / shelf life American Pharmaceutical Ingredients LLC NDC 58597-7042-3 D-0591-2018
Class II · Moderate risk

Fluticasone propionate USP

CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

Terminated Stability / shelf life American Pharmaceutical Ingredients LLC NDC 58597-8276-3 D-0539-2018
Class II · Moderate risk

Cyanocobalamin USP

CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

Terminated Stability / shelf life American Pharmaceutical Ingredients LLC NDC 58597-8044-1 D-0538-2018